An observational study of carbidopa and levodopa use with a new dispensing device and app in patients with Parkinson's disease
Sweden- Participants:18–64 years · 65+ years
- Substances:Carbidopa
- Sponsor:Navamedic AB
Rare diseases
Investigational molecules
Locations
Goteborgsvagen 74, 433 63, Sweden
Navamedic AB is involved in clinical research centered on Parkinson’s disease, with a focus on patient-facing support tools linked to treatment use and daily disease management.
The sponsor’s research activity reflects interest in practical treatment support within neurology, particularly solutions that affect how patients interact with their medication in routine care.
Clinical trials run by this sponsor – those enrolling participants first.
SwedenIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.